Home / Themes / MedTech Long '24: Lab & Life Sciences Tools
MedTech Long '24: Lab & Life Sciences Tools (view performance)
Last updated
Theme thesis · 3/5 sections · Tickers 6 with notes · 4 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsThe thesis for MedTech '24: Lab & Life Sciences Tools is bullish as of Spring 2025. The sector is poised to benefit from a cyclical rebound and the ongoing tren
Thesis
The thesis for MedTech '24: Lab & Life Sciences Tools is bullish as of Spring 2025. The sector is poised to benefit from a cyclical rebound and the ongoing trend of reshoring biopharma supply chains, driven by geopolitical shifts and policy support under the Trump administration. Key players in the sector are expected to capitalize on increased demand for life sciences tools and equipment, fueled by innovation and the need for more localized production capabilities.
Bull case
The Trump administration's focus on reshoring biopharma supply chains is expected to increase demand for domestic life sciences tools and equipment.
Continued innovation in life sciences and a shift towards outsourcing and onshoring are creating new opportunities for companies in this sector.
Positive earnings reports from key players like DHR and TMO indicate a bottoming out of the cyclical downturn in bioprocessing, suggesting a favorable environment for growth.
Bear case
Potential trade tensions and regulatory hurdles could disrupt supply chains and impact growth projections for companies heavily reliant on international markets.
High interest rates may continue to challenge capital-intensive businesses, affecting their ability to fund innovation and expansion.
The market has not fully priced in the nuances of who will benefit from reshoring, leading to potential misalignments in valuation.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| Bioprocessing Order Volume | Quarterly | Demand trends for life sciences tools | Google_Sheets |
| Trade Policy Announcements | Ad-hoc | Impact of geopolitical shifts | Google_Sheets |
| R&D Investment Levels | Annually | Industry commitment to innovation | Google_Sheets |
Upcoming Catalysts
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| A_6dd05b00 | later this year | 2026-08-12 | 2026-12-31 | Completion of the Biocare acquisition. | The acquisition is expected to provide robust long-term growth, strong strategic fit, and opportunities for synergy realization, making the financial returns highly attractive. | Ticker | 2026-05-27 | earnings_transcript | A (ticker) |
| DHR_2e0838de | later this year | 2026-07-21 | 2026-12-31 | Completion of the pending acquisition of Masimo, subject to customary closing conditions and regulatory approvals. | This strategic acquisition is expected to be accretive to adjusted diluted net EPS in the first full year post-acquisition and deliver high single-digit return on invested capital by the fifth year, enhancing Danaher's acute care diagnostics strategy and offering significant synergies. | Ticker | 2026-04-21 | earnings_transcript | DHR (ticker) |
| DHR_ba441a9a | for the year | 2026-07-01 | 2026-12-31 | Further improvement in Life Sciences end markets, including accelerated growth in China and faster conversion of biotech funding into orders. | This would allow Danaher to achieve the higher end of its 2026 core revenue and adjusted EPS guidance, signaling stronger underlying demand and a more robust recovery in key market segments. | Ticker | 2026-04-21 | earnings_transcript | DHR (ticker) |
| TMO_3fae1221 | over time | 2026-07-01 | 2026-12-31 | A return to stronger growth in the China market, beyond the current muted expectations. | China is a significant market for TMO, and a return to stronger growth, not currently factored into guidance, would provide an incremental tailwind and upside to overall revenue. | Ticker | 2026-04-23 | earnings_transcript | TMO (ticker) |
| A_8bb5aafd | at the end of our fiscal year | 2026-10-01 | 2026-10-31 | Initial orders from large pharma customers for reshoring operations to the U.S. | This represents a strong tailwind for Agilent's downstream manufacturing QA/QC workflows, aligning with broader industry trends and potentially driving future revenue starting in FY27. | Ticker | 2026-05-27 | earnings_transcript | A (ticker) |
| BRKR_2faf8429 | fourth quarter of 2026 | 2026-10-01 | 2026-12-31 | Completion of semiconductor customer deliveries that shifted from Q3 to Q4 2026, contributing to significantly higher volume in the quarter. | This $20 million revenue shift is expected to drive meaningful sequential and year-over-year increases in Q4 2026 organic revenue growth, operating margin, and EPS, crucial for achieving full-year guidance. | Ticker | 2026-08-04 | earnings_transcript | BRKR (ticker) |
| BRKR_9d0e9826 | coming into the fourth quarter | 2026-10-01 | 2026-12-31 | Delivery and installation of an ultra-high field NMR system in Q4 2026. | The delivery of this high-value system is expected to contribute to a favorable mix and significantly higher volume in Q4, boosting revenue and profitability for the quarter. | Ticker | 2026-08-04 | earnings_transcript | BRKR (ticker) |
| DHR_f825acc1 | by the end of the year | 2026-10-01 | 2026-12-31 | Abatement of policy headwinds in China diagnostics, normalization of respiratory revenue, and improved year-over-year comparisons in Life Sciences. | The resolution of these headwinds is projected to drive an acceleration in Danaher's core revenue growth, enabling the company to achieve mid-single-digit core growth by the end of Q4 2026. | Ticker | 2026-04-21 | earnings_transcript | DHR (ticker) |
| DHR_0a68fb32 | Q4 | 2026-10-01 | 2026-12-31 | A stronger-than-typical seasonal respiratory infection rate in the fourth quarter of 2026. | A robust respiratory season would contribute to Danaher's goal of returning to an endemic $1.8 billion respiratory revenue rate and help achieve the higher end of its full-year 2026 guidance. | Ticker | 2026-04-21 | earnings_transcript | DHR (ticker) |
| AVTR_5d6352c4 | Tuesday, December 8, in New York City | 2026-12-08 | 2026-12-08 | Avantor to host its Investor Day in New York City. | This event will provide a comprehensive overview of the business strategy, financial objectives, and an opportunity for investors to engage with the leadership team, potentially including updates on portfolio optimization. | Ticker | 2026-07-29 | earnings_transcript | AVTR (ticker) |